Stock Track | AKESO Soars 9.74% Intraday on Positive Phase III Lung Cancer Trial Data at ASCO

Stock Track06-01

AKESO's stock price surged 9.74% during intraday trading on Monday, following a significant gap up at the market open.

The sharp rise was driven by the release of updated positive results from the Phase III HARMONi-6 study for the company's PD-1/VEGF bispecific antibody, Ivonescimab, in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer. The data, presented at the ASCO Plenary Session, showed the Ivonescimab group achieved a 34% reduction in the risk of death compared to the control group, with a statistically significant overall survival benefit.

The trial results, which were also published in *The Lancet*, mark a significant milestone as the first time in 61 years that Phase III results for a first-in-class novel drug from China have been selected for an ASCO Plenary Session report, indicating their potential to reshape clinical practice.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198658750?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198658750","market":"us","top_or_hot":-1,"title":"Stock Track | AKESO Soars 9.74% Intraday on Positive Phase III Lung Cancer Trial Data at ASCO","media":"Stock Track","content":"<p>AKESO's stock price surged 9.74% during intraday trading on Monday, following a significant gap up at the market open.</p><p>The sharp rise was driven by the release of updated positive results from the Phase III HARMONi-6 study for the company's PD-1/VEGF bispecific antibody, Ivonescimab, in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer. The data, presented at the ASCO Plenary Session, showed the Ivonescimab group achieved a 34% reduction in the risk of death compared to the control group, with a statistically significant overall survival benefit.</p><p>The trial results, which were also published in *The Lancet*, mark a significant milestone as the first time in 61 years that Phase III results for a first-in-class novel drug from China have been selected for an ASCO Plenary Session report, indicating their potential to reshape clinical practice.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AKESO Soars 9.74% Intraday on Positive Phase III Lung Cancer Trial Data at ASCO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AKESO Soars 9.74% Intraday on Positive Phase III Lung Cancer Trial Data at ASCO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-01 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO's stock price surged 9.74% during intraday trading on Monday, following a significant gap up at the market open.</p><p>The sharp rise was driven by the release of updated positive results from the Phase III HARMONi-6 study for the company's PD-1/VEGF bispecific antibody, Ivonescimab, in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer. The data, presented at the ASCO Plenary Session, showed the Ivonescimab group achieved a 34% reduction in the risk of death compared to the control group, with a statistically significant overall survival benefit.</p><p>The trial results, which were also published in *The Lancet*, mark a significant milestone as the first time in 61 years that Phase III results for a first-in-class novel drug from China have been selected for an ASCO Plenary Session report, indicating their potential to reshape clinical practice.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1198658750","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198658750","pubTimestamp":1780277621,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AKESO's stock price surged 9.74% during intraday trading on Monday, following a significant gap up at the market open.The sharp rise was driven by the release of updated positive results from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"个股追踪|ASCO肺癌III期试验数据阳性康方生物盘中大涨9.74%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"AKESO's stock price surged 9.74% during intraday trading on Monday, following a significant gap up at the market open.The sharp rise was driven by the release of updated positive results from the Phase III HARMONi-6 study for the company's PD-1/VEGF bispecific antibody, Ivonescimab, in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer. The data, presented at the ASCO Plenary Session, showed the Ivonescimab group achieved a 34% reduction in the risk of death compared to the control group, with a statistically significant overall survival benefit.The trial results, which were also published in *The Lancet*, mark a significant milestone as the first time in 61 years that Phase III results for a first-in-class novel drug from China have been selected for an ASCO Plenary Session report, indicating their potential to reshape clinical practice.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198658750","isCrawlerRequest":true}